Forecast

Buy	7
Hold	1
Sell	0

News Go to news feed

Zura Bio expects pivotal Tibulizumab study results within six months

At the Cantor Fitzgerald Healthcare Conference, Zura Bio said it expects important clinical data for its lead candidate Tibulizumab within six months, including results for hidradenitis suppurativa in Q4 2024 and for systemic sclerosis in the first half of 2025. Tibulizumab is a bispecific antibody targeting IL-17 and BAFF; the company highlights a tetravalent design and hopes to overcome the limits of single-target therapies. The hidradenitis study was overenrolled at 247 patients and selected change in abscess and nodule count as the primary endpoint; early safety data show low rates of treatment-emergent anti-drug antibodies. Due to limited funds, Zura is focusing on this program for now. » More on de.investing.com

Financials

In the last quarter, ZURA BIO LTD CL.A Aktie had revenue of €0 and net profit of -€26.3M

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-26.3M	64.47%
EBITDA	-29.31M	62.35%

Fundamentals

Metric	Value
Market capitalization	€467.39M
Number of shares	95M
52-week high/low	€6.00 - €1.61
Dividends	No
Beta	-0.04
P/E ratio	-5.05
PEG ratio	0.10
P/B ratio	3.67
P/S ratio	0.00

Company profile

Zura Bio Limited, ein Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung neuartiger Arzneimittel für Immun- und Entzündungserkrankungen. Es entwickelt ZB-168, einen Hemmstoff gegen IL7R, der sich auf Krankheiten auswirkt, die durch die biologischen IL7- und TSLP-Signalwege ausgelöst werden, sowie Torudokimab, einen monoklonalen Antikörper, der IL33 neutralisiert und sich in der Phase 2 der klinischen Entwicklung befindet. Das Unternehmen hat seinen Sitz in San Diego, Kalifornien.